Disease · MONDO_0019313
Trials11
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
1 to 11 of 11
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02335242 | Sildenafil for the Treatment of Lymphatic Malformations | Phase 2 | 22 | 2022-11-17 | Lymphatic Malformations, Lymphatic Diseases | SILDENAFIL | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01290484 | A Study to Evaluate Sildenafil for the Treatment of Lymphatic Malformations | Phase 1/2 | 7 | 2014-06-12 | Lymphangioma | SILDENAFIL | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT06943703 | Bleomycin as an Effective and Curative Adjunct Therapy for Lymphangioma | 809 | Lymphangioma, Lymphatic Malformations | BLEOMYCIN | Open Targets' reading of its record | ClinicalTrials.gov | ||
| NCT05948943 | Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. | Phase 2/3 | 232 | Lymphatic Malformations | ALPELISIB | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT06437158 | Use of Bleomycin in the Sclerotherapy of Lymphatic Malformations for Pediatric Patients | Phase 2 | 200 | Lymphatic Malformation | BLEOMYCIN | Its record names the disease | ClinicalTrials.gov | |
| NCT07579962 | Treatment of Low-flow Vascular Malformations With Bleomycin Electrosclerotherapy (BEST) | Phase 2 | 140 | Vascular Malformations | BLEOMYCIN | Its record names the disease | ClinicalTrials.gov | |
| NCT07320001 | Injection Sclerotherapy With Bleomycin VS Doxycycline in Patients With Lymphatic Malformations | Phase 2 | 92 | Lymphatic Abnormality | BLEOMYCIN, DOXYCYCLINE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT03243019 | Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations | Phase 2 | 28 | Lymphatic Malformation, Pediatric | SIROLIMUS | Its record names the disease | ClinicalTrials.gov | |
| NCT04861064 | Weekly Sirolimus Therapy | Phase 2 | 24 | Venous Malformation, Lymphatic Malformation | SIROLIMUS | Its record names the disease | ClinicalTrials.gov | |
| NCT04128722 | TOPical Sirolimus in linGUal Microcystic Lymphatic Malformation -TOPGUN | Phase 2 | 12 | Lingual Microcystic Lymphatic Malformations | SIROLIMUS | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT01212965 | Selenium in the Treatment of Complicated Lymphatic Malformations | Phase 1 | 5 | Lymphatic Malformations | SELENIUM | Open Targets' reading of its record | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019313/trials